EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CMKLR1 Antagonist Alpha-NETA Protects against Diabetic Nephropathy in Mice

Zining Peng, Xueyi Wang, Qing Zhu, Huili Wang, Bing Li, Xinxin Pang, Jiarui Han

Kidney and Blood Pressure Research · 2023

DOI: 10.1159/000530763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2023. Verfasst von Zining Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Second clinical medical College, Henan University of Chinese Medicine, Zhengzhou, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Diabetic nephropathy (DN) is a common complication in diabetic patients. Chemerin, a novel adipokine, has been associated with renal damage in DN. The chemerin chemokine-like receptor 1 (CMKLR1) has been reported to participate in DN. In this study, we aimed to investigate the effect of a CMKLR1 antagonist, 2-(anaphthoyl)ethyltrimethylammonium iodide (α-NETA), on DN.

Methods

To induce diabetes, 8-week-old male C57BL/6J mice were given a single intraperitoneal injection of 65 mg/kg streptozotocin (STZ). Diabetic mice were randomly assigned to receive daily doses of 0, 5, or 10 mg/kg α-NETA for 4 weeks. Results: α-NETA dose-dependently induced body weight and reduced fasting blood glucose levels in STZ-induced diabetic mice. Furthermore, α-NETA significantly reduced the expressions of renal injury markers, including serum creatinine, kidney weight/body weight, urine volume, total proteins, and albumin in the urine, and increased creatinine clearance. Periodic acid-Schiff staining also indicated that α-NETA could effectively ameliorate renal injuries in DN mice. In addition, α-NETA inhibited renal inflammation and the expressions of chemerin and CMKLR1 in mice with DN.

Conclusion

In summary, our findings suggested that α-NETA has beneficial effects on the management of DN. Specifically, α-NETA effectively ameliorated renal damage and inflammation in a dose-dependent manner in mice with DN. Thus, targeting the chemerin and CMKLR1 axis with α-NETA may be a promising therapeutic strategy for the treatment of DN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesDiabetes Mellitus, ExperimentalHumansMiceMaleAnimalsMice, Inbred C57BLKidneyInflammationBody WeightReceptors, ChemokineChemokinesIntercellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

2-(Anaphthoyl)ethyltrimethylammonium iodideChemerinChemokine-like receptor 1Diabetic neuropathyInflammation

Substanzen

CMKLR1 protein, humanReceptors, ChemokineCMKLR1 protein, mousechemerin protein, mouseChemokinesIntercellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Second clinical medical College, Henan University of Chinese Medicine, Zhengzhou, China.
  • Department of Nephropathy, Henan Provincial Hospital of Traditional Chinese Medicine (The Second Hospital Affiliated to Henan University of Chinese Medicine), Zhengzhou, China.

Zitieren

APA

Peng, Z., Wang, X., Zhu, Q., Wang, H., Li, B., Pang, X., & Han, J. (2023). CMKLR1 Antagonist Alpha-NETA Protects against Diabetic Nephropathy in Mice. Kidney and Blood Pressure Research. https://doi.org/10.1159/000530763

Vancouver

Peng Z, Wang X, Zhu Q, Wang H, Li B, Pang X, et al. CMKLR1 Antagonist Alpha-NETA Protects against Diabetic Nephropathy in Mice. Kidney and Blood Pressure Research. 2023. doi:10.1159/000530763

BibTeX
@article{Peng2023,
  author = {Peng, Zining and Wang, Xueyi and Zhu, Qing and Wang, Huili and Li, Bing and Pang, Xinxin and Han, Jiarui},
  title = {CMKLR1 Antagonist Alpha-NETA Protects against Diabetic Nephropathy in Mice},
  journal = {Kidney and Blood Pressure Research},
  year = {2023},
  doi = {10.1159/000530763}
}
Kostenlos starten →